Skip to content
Screener

Retained Earnings at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$14.59B+42.3%
Jade Biosciences logo
Jade BiosciencesJBIO
-$214.76M+8.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$881.9M-71.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$110.94M-1.3%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
-$102.18M
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$1.57B-32.7%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
AssetsMarch 31, 2026 / (unaudited)December 31, 2025
Stockholders' Equity:
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock $0.0001 par value; 200,000,000 shares authorized; 92,403,744, and 90,922,868 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively99
Additional paid-in capital1,609,5961,588,721
Accumulated deficit(1,509,815)(1,472,713)
Accumulated other comprehensive loss(1,062)(1,189)
Total stockholders' equity98,728114,828
Total liabilities and stockholders' equity$555,188$605,191

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s retained earnings?
Travere Therapeutics, Inc. (TVTX) reported retained earnings of -$1.51B in Q1 2026.
How has Travere Therapeutics, Inc.'s retained earnings changed year-over-year?
Travere Therapeutics, Inc.'s retained earnings decreased by 1.4% year-over-year, from -$1.49B to -$1.51B.
What is the long-term trend for Travere Therapeutics, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s retained earnings has grown at a 20.2% compound annual growth rate (CAGR), from -$585.88M to -$1.47B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Travere Therapeutics, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude